Fluphenazine Inj Rx
Generic Name and Formulations:
Fluphenazine HCl 2.5 mg/mL; vial.
Various generic manufacturers
Indications for Fluphenazine Inj:
Initially: 1.25mg IM every 6–8 hrs; max 10mg daily.
Coma. CNS or bone marrow depression. Liver disease. Subcortical brain damage. Blood dyscrasias.
Cardiovascular or renal disease. Pheochromocytoma. Seizures. Glaucoma. History of breast cancer. Exposure to extreme heat or organophosphates. Gradually reduce to lowest effective maintenance dose. Monitor blood, liver, renal, and ocular function. Mental retardation. Surgery. Pregnancy. Nursing mothers.
Potentiates anticholinergics, CNS depression with alcohol and other CNS depressants; both drugs with propranolol. Antagonized by anticholinergics. Decreased guanethidine effects. May cause false (+) pregnancy test.
Drowsiness, anticholinergic and other autonomic effects, insomnia, restlessness, rash, photosensitivity, tardive dyskinesia, blood dyscrasias, jaundice, pneumonia, hypertension, retinopathy, lowered seizure threshold, extrapyramidal reactions, neuroleptic malignant syndrome, weight changes, endocrine effects.
Formerly known under the brand names Prolixin (tabs, concentrate, elixir, inj); Permitil (tabs, concentrate); Prolixin Decanoate (decanoate inj).
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D